Eli Lilly is on the verge of becoming the first pharmaceutical company to sustain a $1 trillion market capitalization, briefly touching that mark in November and now trading around $960 billion. This milestone reflects a nearly 200% rally over the past three years, driven by the rapid adoption of its weight-loss and diabetes therapies. Investors have rewarded the company for combining the defensive characteristics of a large‐cap pharmaceutical with the high‐growth profile more typical of technology firms.

In the most recent quarter, sales of tirzepatide products Zepbound and Mounjaro generated over $10 billion, lifting overall revenue by 54% year-over-year. These therapies have become the top prescribed options for obesity and type 2 diabetes, with head-to-head trials showing superior efficacy to competitors. Gross margins exceeded 83%, underscoring the high profitability of the franchise, while the company maintained a dividend yield of 0.58% to support income-focused investors.

Lilly is in advanced talks to acquire Ventyx Biosciences for more than $1 billion, adding oral therapies targeting Crohn’s disease and rheumatoid arthritis, plus a mid-stage candidate for obesity-linked cardiovascular disease. Earlier this week, the company also struck a multi-year AI-driven research and licensing agreement with Nimbus Therapeutics to develop new oral obesity and metabolic treatments. These moves complement internal efforts on an oral weight-loss candidate under regulatory review that could outpace rivals by eliminating dietary restrictions.